Actinium Pharmaceuticals, Inc.

• Booth: 116

Actinium Pharmaceuticals, Inc. is a late-stage, publicly traded biopharma company developing targeted radiotherapies for patients with high unmet needs. Our vision is an integrated specialty oncology company built on innovative R&D capabilities in targeted radiotherapy. Our lead program, Iomab-B, completed enrollment of its pivotal Phase 3 trial.  This data, expected to support a BLA filing, will be reported in Q1 2023. Iomab-B has the potential to address the unmet needs of patients with R/R AML by enabling a bone marrow transplant, the only potentially curative treatment option for the population. We are also advancing Actimab-A, being studied in Phase 1/2 trials for patients with R/R blood cancers. Underpinning our clinical programs is our technology platform supported by >170 patents and technical expertise. Ongoing research collaborations focus on solid tumor theranostics – Astellas Pharma, CD47 immunotherapy combinations – EpicentRx, Inc. and HER3+ solid tumors – AVEO Oncology.  

Brands: I-131 apamistamab [Iomab-B; I-131 BC8] is the investigational drug candidate in SIERRA: the only Phase 3 trial offering allogeneic HCT to patients with active, relapsed/refractory AML.